FM 101Alternative Names: FM-101
Latest Information Update: 02 Aug 2011
At a glance
- Originator Femta Pharmaceuticals
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Crohn's disease; Multiple myeloma; Rheumatoid arthritis